药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Urelumab
The risk or severity of adverse effects can be increased when Urelumab is combined with Polatuzumab vedotin.
Difenoxin
Visilizumab
The risk or severity of adverse effects can be increased when Visilizumab is combined with Polatuzumab vedotin.
Difenoxin
Gantenerumab
The risk or severity of adverse effects can be increased when Gantenerumab is combined with Polatuzumab vedotin.
Difenoxin
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Polatuzumab vedotin.
Difenoxin
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Polatuzumab vedotin.
Difenoxin
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Polatuzumab vedotin.
Difenoxin
Rilotumumab
The risk or severity of adverse effects can be increased when Rilotumumab is combined with Polatuzumab vedotin.
Difenoxin
Crenezumab
The risk or severity of adverse effects can be increased when Crenezumab is combined with Polatuzumab vedotin.
Difenoxin
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Polatuzumab vedotin.
Difenoxin
Varlilumab
The risk or severity of adverse effects can be increased when Varlilumab is combined with Polatuzumab vedotin.
Difenoxin
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Polatuzumab vedotin.
Difenoxin
Vadastuximab Talirine
The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Polatuzumab vedotin.
Difenoxin
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Polatuzumab vedotin.
Difenoxin
Landogrozumab
The risk or severity of adverse effects can be increased when Landogrozumab is combined with Polatuzumab vedotin.
Difenoxin
Seribantumab
The risk or severity of adverse effects can be increased when Seribantumab is combined with Polatuzumab vedotin.
Difenoxin
Ligelizumab
The risk or severity of adverse effects can be increased when Ligelizumab is combined with Polatuzumab vedotin.
Difenoxin
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Polatuzumab vedotin.
Difenoxin
Emibetuzumab
The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Polatuzumab vedotin.
Difenoxin
Dalotuzumab
The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Polatuzumab vedotin.
Difenoxin
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Polatuzumab vedotin.